161 related articles for article (PubMed ID: 38344849)
1. KIT/PDGFRA inhibitors for the treatment of gastrointestinal stromal tumors: getting to the gist of the problem.
Cicala CM; Olivares-Rivas I; Aguirre-Carrillo JA; Serrano C
Expert Opin Investig Drugs; 2024 Mar; 33(3):159-170. PubMed ID: 38344849
[TBL] [Abstract][Full Text] [Related]
2. New Tyrosine Kinase Inhibitors for the Treatment of Gastrointestinal Stromal Tumors.
Serrano C; Bauer S
Curr Oncol Rep; 2022 Feb; 24(2):151-159. PubMed ID: 35061196
[TBL] [Abstract][Full Text] [Related]
3. Circulating tumor DNA analysis of the phase III VOYAGER trial: KIT mutational landscape and outcomes in patients with advanced gastrointestinal stromal tumor treated with avapritinib or regorafenib.
Serrano C; Bauer S; Gómez-Peregrina D; Kang YK; Jones RL; Rutkowski P; Mir O; Heinrich MC; Tap WD; Newberry K; Grassian A; Shi H; Bialick S; Schöffski P; Pantaleo MA; von Mehren M; Trent JC; George S
Ann Oncol; 2023 Jul; 34(7):615-625. PubMed ID: 37105265
[TBL] [Abstract][Full Text] [Related]
4. The multifaceted landscape behind imatinib resistance in gastrointestinal stromal tumors (GISTs): A lesson from ripretinib.
Di Vito A; Ravegnini G; Gorini F; Aasen T; Serrano C; Benuzzi E; Coschina E; Monesmith S; Morroni F; Angelini S; Hrelia P
Pharmacol Ther; 2023 Aug; 248():108475. PubMed ID: 37302758
[TBL] [Abstract][Full Text] [Related]
5. Identifying Secondary Mutations in Chinese Patients with Imatinib-Resistant Gastrointestinal Stromal Tumors (GISTs) by Next Generation Sequencing (NGS).
Du J; Wang S; Wang R; Wang SY; Han Q; Xu HT; Yang P; Liu Y
Pathol Oncol Res; 2020 Jan; 26(1):91-100. PubMed ID: 31758409
[TBL] [Abstract][Full Text] [Related]
6. Antitumor Efficacy of the Novel KIT Inhibitor IDRX-42 (Formerly M4205) in Patient- and Cell Line-Derived Xenograft Models of Gastrointestinal Stromal Tumor (GIST).
De Sutter L; Wozniak A; Verreet J; Vanleeuw U; De Cock L; Linde N; Drechsler C; Esdar C; Sciot R; Schöffski P
Clin Cancer Res; 2023 Aug; 29(15):2859-2868. PubMed ID: 37223931
[TBL] [Abstract][Full Text] [Related]
7. [Gastrointestinal stromal tumors (GIST)].
Jaros D; Bozic B; Sebesta C
Wien Med Wochenschr; 2023 Jun; 173(9-10):201-205. PubMed ID: 36155864
[TBL] [Abstract][Full Text] [Related]
8. Targeting the translational machinery in gastrointestinal stromal tumors (GIST): a new therapeutic vulnerability.
Lee DM; Sun A; Patil SS; Liu L; Rao AV; Trent PT; Ali AA; Liu C; Rausch JL; Presutti LD; Kaczorowski A; Schneider F; Amankulor NM; Shuda M; Duensing A
Sci Rep; 2022 May; 12(1):8275. PubMed ID: 35585158
[TBL] [Abstract][Full Text] [Related]
9. Genomic Subtypes of GISTs for Stratifying Patient Response to Sunitinib following Imatinib Resistance: A Pooled Analysis and Systematic Review.
Tan S; Chen P; Ji J; Guo S; Yu D; Asakawa T; Zhou Y; Abe M; Zong L
Dis Markers; 2018; 2018():1368617. PubMed ID: 30224936
[TBL] [Abstract][Full Text] [Related]
10. Imatinib treatment for gastrointestinal stromal tumour (GIST).
Lopes LF; Bacchi CE
J Cell Mol Med; 2010 Jan; 14(1-2):42-50. PubMed ID: 19968734
[TBL] [Abstract][Full Text] [Related]
11. KIT and BRAF heterogeneous mutations in gastrointestinal stromal tumors after secondary imatinib resistance.
Zheng S; Huang KE; Pan YL; Zhou Y; Pan SD; Li X; Jia J; Zheng XL; Tao DY
Gastric Cancer; 2015 Oct; 18(4):796-802. PubMed ID: 25182956
[TBL] [Abstract][Full Text] [Related]
12. Molecular analysis of secondary kinase mutations in imatinib-resistant gastrointestinal stromal tumors.
Lim KH; Huang MJ; Chen LT; Wang TE; Liu CL; Chang CS; Liu MC; Hsieh RK; Tzen CY
Med Oncol; 2008; 25(2):207-13. PubMed ID: 18488160
[TBL] [Abstract][Full Text] [Related]
13. Novel V600E BRAF mutations in imatinib-naive and imatinib-resistant gastrointestinal stromal tumors.
Agaram NP; Wong GC; Guo T; Maki RG; Singer S; Dematteo RP; Besmer P; Antonescu CR
Genes Chromosomes Cancer; 2008 Oct; 47(10):853-9. PubMed ID: 18615679
[TBL] [Abstract][Full Text] [Related]
14. Ripretinib for the treatment of advanced gastrointestinal stromal tumor.
Zalcberg JR
Therap Adv Gastroenterol; 2021; 14():17562848211008177. PubMed ID: 33948116
[TBL] [Abstract][Full Text] [Related]
15. Novel Insights into the Treatment of Imatinib-Resistant Gastrointestinal Stromal Tumors.
Serrano C; George S; Valverde C; Olivares D; García-Valverde A; Suárez C; Morales-Barrera R; Carles J
Target Oncol; 2017 Jun; 12(3):277-288. PubMed ID: 28478525
[TBL] [Abstract][Full Text] [Related]
16. Complementary activity of tyrosine kinase inhibitors against secondary kit mutations in imatinib-resistant gastrointestinal stromal tumours.
Serrano C; Mariño-Enríquez A; Tao DL; Ketzer J; Eilers G; Zhu M; Yu C; Mannan AM; Rubin BP; Demetri GD; Raut CP; Presnell A; McKinley A; Heinrich MC; Czaplinski JT; Sicinska E; Bauer S; George S; Fletcher JA
Br J Cancer; 2019 Mar; 120(6):612-620. PubMed ID: 30792533
[TBL] [Abstract][Full Text] [Related]
17. Molecular basis for primary and secondary tyrosine kinase inhibitor resistance in gastrointestinal stromal tumor.
Gounder MM; Maki RG
Cancer Chemother Pharmacol; 2011 Jan; 67 Suppl 1(Suppl 1):S25-43. PubMed ID: 21116624
[TBL] [Abstract][Full Text] [Related]
18. The role of KIT in the management of patients with gastrointestinal stromal tumors.
Hornick JL; Fletcher CD
Hum Pathol; 2007 May; 38(5):679-87. PubMed ID: 17437861
[TBL] [Abstract][Full Text] [Related]
19. Correlation of imatinib resistance with the mutational status of KIT and PDGFRA genes in gastrointestinal stromal tumors: a meta-analysis.
Lee JH; Kim Y; Choi JW; Kim YS
J Gastrointestin Liver Dis; 2013 Dec; 22(4):413-8. PubMed ID: 24369323
[TBL] [Abstract][Full Text] [Related]
20. New insights into the clinical management of advanced gastrointestinal stromal tumors.
Italiano A
Expert Opin Pharmacother; 2021 Mar; 22(4):439-447. PubMed ID: 33307872
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]